211 related articles for article (PubMed ID: 34269313)
21. Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma.
Ando Y; Kawaoka T; Amioka K; Naruto K; Ogawa Y; Yoshikawa Y; Kikukawa C; Kosaka Y; Uchikawa S; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Mori N; Takaki S; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Moriya T; Naeshiro N; Takahashi S; Imamura M; Chayama K; Aikata H
Oncology; 2021; 99(8):507-517. PubMed ID: 33946070
[TBL] [Abstract][Full Text] [Related]
22. Effect of palonosetron and dexamethasone administration on the prevention of gastrointestinal symptoms in hepatic arterial chemoembolization with epirubicin.
Sakamoto T; Saito Y; Kobayashi M; Yamada T; Takekuma Y; Nakai M; Ogawa K; Iseki K; Sugawara M
Support Care Cancer; 2020 Jul; 28(7):3251-3257. PubMed ID: 31732854
[TBL] [Abstract][Full Text] [Related]
23. Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 Patients.
Gomes AS; Monteleone PA; Sayre JW; Finn RS; Sadeghi S; Tong MJ; Britten CD; Busuttil RW
AJR Am J Roentgenol; 2017 Oct; 209(4):722-732. PubMed ID: 28705059
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the Efficacy of Two Microsphere Embolic Agents for Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma Patients.
Lee SH; Lin CY; Hsu YC; Liu YS; Chuang MT; Ou MC
Cancer Res Treat; 2020 Jan; 52(1):24-30. PubMed ID: 31048665
[TBL] [Abstract][Full Text] [Related]
25. Switching the loaded agent from epirubicin to cisplatin: salvage transcatheter arterial chemoembolization with drug-eluting microspheres for unresectable hepatocellular carcinoma.
Seki A; Hori S
Cardiovasc Intervent Radiol; 2012 Jun; 35(3):555-62. PubMed ID: 21562932
[TBL] [Abstract][Full Text] [Related]
26. Risk Factors for the Development of Postembolization Syndrome after Transarterial Chemoembolization for Hepatocellular Carcinoma Treatment.
Lima M; Dutra S; Gomes FV; Bilhim T; Coimbra É
Acta Med Port; 2018 Jan; 31(1):22-29. PubMed ID: 29573765
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion.
Ye JZ; Chen JZ; Li ZH; Bai T; Chen J; Zhu SL; Li LQ; Wu FX
World J Gastroenterol; 2017 Nov; 23(41):7415-7424. PubMed ID: 29151695
[TBL] [Abstract][Full Text] [Related]
28. CalliSpheres Drug-Eluting Bead Transcatheter Arterial Chemoembolization Presents With Better Efficacy and Equal Safety Compared to Conventional TACE in Treating Patients With Hepatocellular Carcinoma.
Xiang H; Long L; Yao Y; Fang Z; Zhang Z; Zhang Y
Technol Cancer Res Treat; 2019 Jan; 18():1533033819830751. PubMed ID: 30862264
[TBL] [Abstract][Full Text] [Related]
29. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
[TBL] [Abstract][Full Text] [Related]
30. Dexamethasone Prophylaxis to Alleviate Postembolization Syndrome after Transarterial Chemoembolization for Hepatocellular Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Study.
Yang H; Seon J; Sung PS; Oh JS; Lee HL; Jang B; Chun HJ; Jang JW; Bae SH; Choi JY; Yoon SK
J Vasc Interv Radiol; 2017 Nov; 28(11):1503-1511.e2. PubMed ID: 28941589
[TBL] [Abstract][Full Text] [Related]
31. Postintervention Interleukin-6 (IL-6) Level, Rather than the Pretreatment or Dynamic Changes of IL-6, as an Early Practical Marker of Tumor Response in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
Wu Y; Fan W; Xue M; Zhong B; Zhang S; Wang Y; Yao W; Zhao Y; Li J
Oncologist; 2019 Dec; 24(12):e1489-e1495. PubMed ID: 31249138
[TBL] [Abstract][Full Text] [Related]
32. A differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function.
Nam JY; Choe AR; Sinn DH; Lee JH; Kim HY; Yu SJ; Kim YJ; Yoon JH; Lee JM; Chung JW; Choi SY; Lee JK; Baek SY; Lee HA; Kim TH; Yoo K
BMC Cancer; 2020 Jun; 20(1):504. PubMed ID: 32487089
[TBL] [Abstract][Full Text] [Related]
33. Predictive model for acute abdominal pain after transarterial chemoembolization for liver cancer.
Bian LF; Zhao XH; Gao BL; Zhang S; Ge GM; Zhan DD; Ye TT; Zheng Y
World J Gastroenterol; 2020 Aug; 26(30):4442-4452. PubMed ID: 32874056
[TBL] [Abstract][Full Text] [Related]
34. Risk of hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma: predictive value of the monoethylglycinexylidide test.
Huang YS; Chiang JH; Wu JC; Chang FY; Lee SD
Am J Gastroenterol; 2002 May; 97(5):1223-7. PubMed ID: 12014732
[TBL] [Abstract][Full Text] [Related]
35. Factors affecting post-embolization fever and liver failure after trans-arterial chemo-embolization in a cohort without background infective hepatitis- a prospective analysis.
Siriwardana RC; Niriella MA; Dassanayake AS; Liyanage CA; Upasena A; Sirigampala C; de Silva HJ
BMC Gastroenterol; 2015 Aug; 15():96. PubMed ID: 26239844
[TBL] [Abstract][Full Text] [Related]
36. A new way: alleviating postembolization syndrome following transcatheter arterial chemoembolization.
Yinglu F; Changquan L; Xiaofeng Z; Bai L; Dezeng Z; Zhe C
J Altern Complement Med; 2009 Feb; 15(2):175-81. PubMed ID: 19216654
[TBL] [Abstract][Full Text] [Related]
37. Construction and Validation of Prediction Model of Severe Abdominal Pain Post-Transarterial Chemoembolization in Patients with HBV-Associated Primary Liver Cancer.
Yang Y; Chen S; Yan Z; Jiao Y; Yan X; Li Y
Comput Math Methods Med; 2022; 2022():5203166. PubMed ID: 35941895
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of transcatheter arterial chemoembolization combined with either
Li Y; Li H; Hu H; Yuan H; Zhao Y
J Cancer Res Ther; 2020; 16(7):1691-1697. PubMed ID: 33565518
[TBL] [Abstract][Full Text] [Related]
39. Serial serum VEGF-A, angiopoietin-2, and endostatin measurements in cirrhotic patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization.
Hsieh MY; Lin ZY; Chuang WL
Kaohsiung J Med Sci; 2011 Aug; 27(8):314-22. PubMed ID: 21802642
[TBL] [Abstract][Full Text] [Related]
40. Update on Transarterial Chemoembolization with Drug-Eluting Microspheres for Hepatocellular Carcinoma.
Nouri YM; Kim JH; Yoon HK; Ko HK; Shin JH; Gwon DI
Korean J Radiol; 2019 Jan; 20(1):34-49. PubMed ID: 30627020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]